BioMedNewsBreaks

MondayApr 12, 2021 2:48 pm

BioMedNewsBreaks – InvestorBrandNetwork and BioMedWire Collaborate to Deliver Incredible Visibility and Reach for DGE’s Upcoming 2021 Events

InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting companies to the investment community through 50+ brands, today announced that it will partner with Dynamic Global Events (“DGE”) as an official media partner for upcoming events in 2021. In addition, BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of the 50+ brands of the InvestorBrandNetwork, will also serve as an official media partner for DGE’s upcoming events. InvestorBrandNetwork and BioMedWire will provide dedicated virtual coverage, including a syndicated article on each event with full dissemination to IBN’s 5000+ strategic syndication partners, social media coverage of…

Continue Reading

MondayApr 12, 2021 12:14 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Presentation of Positive REQORSA(TM) Preclinical Data to Audience of World’s Leading Cancer Researchers

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (“NSCLC”). According to the update, collaborators also presented positive preclinical data for the use of REQORSA in combination with targeted therapies for the treatment of NSCLC. The data were presented at the 2021 American Association of Cancer Research (“AACR”) annual meeting. “We are pleased to have these positive data that provide further support…

Continue Reading

FridayApr 09, 2021 12:19 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expansion of AI-Driven Clinical Models

Predictive Oncology (NASDAQ: POAI) has set sights on other cancers after completing its data generation milestones in a collaborative study with UPMC-Magee Women Hospital. With the comprehensive genomic and transcriptomic sequencing of patient samples now complete, thanks to the study, and patient outcome data having been obtained from UPMC-Magee, “these data will now be used to drive POAI’s AI models of ovarian cancer and their internal ovarian cancer drug re-purposing project.” This is according to an article detailing the matter. “‘The successful generation of high-quality genomic and transcriptomic data from archived materials at Helomics, together with the gathering of historical…

Continue Reading

ThursdayApr 08, 2021 2:20 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Demonstrate Effectiveness vs. Established Chemotherapy Drug in Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP) continues to aggressively pursue FDA approval for its lead drug candidate, Berubicin. The novel candidate is the first anthracycline that appears to be able to cross the blood-brain barrier to combat tumors — stepping up its cancer-fighting potential. Berubicin was the subject of a Phase 1 safety trial conducted by Reata Pharmaceuticals approximately 15 years ago. One of the trial participants has remained alive and cancer-free as of the most recent evaluation late last year, while two other patients in the small study saw reductions of greater than 25% (one being an 80% reduction) in the…

Continue Reading

ThursdayApr 08, 2021 1:47 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Creates Win-Win Solution for Hospitals, Patients

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed a solution set to lower the cost of treating bladder cancer and also help hospitals save money. As a result, Imagin will create a win-win situation for every party involved. The i/Blue(TM) Imaging System, Imagin’s proprietary solution, achieves this in two ways. “By displaying the blue light image that shows the highlighted cancer cells alongside the white light image that shows the full landscape of the bladder, the i/Blue Imaging System will provide surgeons with improved visualization to locate and resect tumors. The overall result is a reduction…

Continue Reading

WednesdayApr 07, 2021 1:07 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Shares Promising Clinical Study Results for HERHEART(TM), Fuel4Thought(TM) Brain Booster

Healthy Extracts (OTCQB: HYEX) is engaged in proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. HYEX recently announced promising clinical study results for two of its subsidiary companies’ leading products: BergaMet North America’s HERHEART(TM) and Ultimate Brain Nutrients’ Fuel4Thought(TM) Brain Booster. “HERHEART(TM) is an exclusive natural supplement that is scientifically formulated specifically for women to support cardiovascular health, including perimenopausal symptoms. The study was conducted in 35 postmenopausal women with sexual dysfunction at the University Magna Graecia of Caranzaro in Italy. Results indicated that patients who were administered HERHEART(TM) reported a 40%…

Continue Reading

TuesdayApr 06, 2021 11:00 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Initiates Phase 2 RESERVOIR Trial for Treatment of COVID-19 GI Infections

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it has initiated its Phase 2 RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide (“FW-1022”) for the treatment of COVID-19-related gastrointestinal (GI) infections. Patient enrollment is expected to begin in April 2021 with topline data anticipated in the first quarter of 2022. “Initiation of the Phase 2 clinical trial of FW-1022 for the treatment of COVID-19 GI infection, or the RESERVOIR trial, is a significant milestone for AzurRx and an important advance in the…

Continue Reading

MondayApr 05, 2021 1:48 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Poised Amid Demand for Rapid Testing Kits

United Medical Equipment (“UME,” “UMEBSNI”), a company offering rapid COVID-19 testing kits, looks positioned to benefit from the high demand for its products. The demand arises from expert recommendations that identifying those infected through rapid testing could help curb the virus and prevent the emergence of new variants. An article about these developments reads, “‘Testing is actually more important now than it was eight months ago because of the high contagiousness rate of these new variants,’ Mara Aspinall, a professor of health practice at Arizona State University, said in a recent interview for NPR. ‘It is critical to stop these…

Continue Reading

MondayApr 05, 2021 12:18 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Virtual Cell & Gene Meeting on the Mediterranean

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, has announced that its COO and Executive VP, Michael Redman, will present at the annual Cell & Gene Meeting on the Mediterranean. The event is slated to take place virtually from April 6-9, 2021, with company presentations available for on-demand viewing throughout the entirety of the conference. Organized by the Alliance for Regenerative Medicine, the four-day virtual conference will feature more than 80 dedicated company presentations by leading public and private companies, highlighting recent technical and clinical achievements in the areas…

Continue Reading

ThursdayApr 01, 2021 12:24 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Key Results from Phase 2b OPTION 2 Clinical Trial

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared key takeaways from its topline results on its Phase 2b OPTION 2 clinical trial. The trial studied AzurRx’s drug candidate MS1819 in the treatment of cystic fibrosis (“CF”) patients with exocrine pancreatic insufficiency (“EPI”). MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. The trial results were shared during a March 31, 2021, conference call hosted by AzurRx president, CEO and chair James Sapirstein and AzurRx chief medical…

Continue Reading